

to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, an expression vector or a plurality of expression vectors according to claim **13**, a cell according to claim **14**, or a composition according to claim **16** or claim **17**.

**26.** The antigen-binding molecule, CAR, nucleic acid or plurality of nucleic acids, expression vector or plurality of expression vectors, cell or composition for use, the use, or the method according to any one of claims **19** to **25**, wherein the method additionally comprises administration of an agent capable of inhibiting signalling mediated by an immune checkpoint inhibitor other than VISTA, optionally wherein the immune checkpoint inhibitor other than VISTA is selected from PD-1, CTLA-4, LAG-3, TIM-3, TIGIT or BTLA.

**27.** A method of inhibiting VISTA-mediated signalling, comprising contacting VISTA-expressing cells with an antigen-binding molecule according to any one of claims **1** to **10**.

**28.** A method for inhibiting the activity of myeloid-derived suppressor cells (MDSCs), the method comprising contacting MDSCs with an antigen-binding molecule according to any one of claims **1** to **10**.

**29.** A method for increasing the number or activity of effector immune cells, the method comprising inhibiting the activity of VISTA-expressing cells with an antigen-binding molecule according to any one of claims **1** to **10**.

**30.** An in vitro complex, optionally isolated, comprising an antigen-binding molecule according to any one of claims **1** to **10** bound to VISTA.

**31.** A method comprising contacting a sample containing, or suspected to contain, VISTA with an antigen-binding

molecule according to any one of claims **1** to **10**, and detecting the formation of a complex of the antigen-binding molecule with VISTA.

**32.** A method of selecting or stratifying a subject for treatment with a VISTA-targeted agent, the method comprising contacting, in vitro, a sample from the subject with an antigen-binding molecule according to any one of claims **1** to **10** and detecting the formation of a complex of the antigen-binding molecule with VISTA.

**33.** Use of an antigen-binding molecule according to any one of claims **1** to **10** as an in vitro or in vivo diagnostic or prognostic agent.

**34.** Use of an antigen-binding molecule according to any one of claims **1** to **10** in a method for detecting, localizing or imaging a cancer, optionally wherein the cancer is selected from: a cancer comprising cells expressing VISTA, a cancer comprising infiltration of cells expressing VISTA, a cancer comprising cancer cells expressing VISTA, a hematological cancer, leukemia, acute myeloid leukemia, lymphoma, B cell lymphoma, T cell lymphoma, multiple myeloma, mesothelioma, a solid tumor, lung cancer, non-small cell lung carcinoma, gastric cancer, gastric carcinoma, colorectal cancer, colorectal carcinoma, colorectal adenocarcinoma, uterine cancer, uterine corpus endometrial carcinoma, breast cancer, triple negative breast invasive carcinoma, liver cancer, hepatocellular carcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma, thyroid cancer, thymoma, skin cancer, melanoma, cutaneous melanoma, kidney cancer, renal cell carcinoma, renal papillary cell carcinoma, head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), ovarian cancer, ovarian carcinoma, ovarian serous cystadenocarcinoma, prostate cancer and/or prostate adenocarcinoma.

\* \* \* \* \*